Astellas takes legal action in hostile pursuit of OSI
This article was originally published in Scrip
Executive Summary
Astellas is continuing down the hostile path in its bid for OSI Pharmaceuticals, with the filing of a US lawsuit aimed at preventing its target from adopting any improper measures to thwart the planned acquisition.